Monopar Therapeutics Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
MNPR
- Investments
-
1
- Share Price
-
$2.98
- (As of Monday Closing)
Monopar Therapeutics General Information
Description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 1000 Skokie Boulevard
- Suite 350
- Wilmette, IL 60091
- United States
+1 (847) 000-0000
Monopar Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.98 | $2.90 | $1.39 - $4.88 | $38.3M | 13.2M | 22.5K | -$0.83 |
Monopar Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 16,326 | 16,326 | 18,074 | 52,227 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (10,537) | (10,537) | (9,127) | (6,386) |
| Net Income | (10,516) | (10,516) | (9,103) | (6,305) |
| Total Assets | 13,227 | 13,227 | 20,522 | 16,869 |
| Total Debt | 8 | 8 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Monopar Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Monopar Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Monopar Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics de
Drug Discovery
Wilmette, IL
12
As of 2022
000.00
00.00
0000-00-00
00000000
000.00
000000
liqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi u
0000 000000000
San Diego, CA
00
As of 0000
00000
000000000
00000
000000
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
Dallas, TX
00
As of 0000
00000
00000000
00000
Add Comparison
Monopar Therapeutics Competitors (58)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioAtla | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
| 0000000 000000 | Formerly VC-backed | Dallas, TX | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Wayne, PA | 000 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000&0 | 00000 |
| 000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
Monopar Therapeutics Patents
Monopar Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021292488-A1 | Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease | Pending | 15-Jun-2020 | 000000000000 | |
| CA-3182769-A1 | Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease | Pending | 15-Jun-2020 | 000000000000 | |
| AU-2018220520-A1 | 3'deamino-3'-(2"-pyrroline-1"-yl)-5-imino-13-deoxyanthracyclines and methods of preparation | Pending | 16-Feb-2017 | 0000000000 | |
| CA-3053417-A1 | 3'-deamino-3'-(2"-pyrroline-1"-yl)-5-imino-13-deoxyanthracyclines and methods of preparation | Pending | 16-Feb-2017 | 0000000000 | |
| EP-3582788-A1 | 3'deamino-3'-(2"-pyrroline-1"-yl)-5-imino-13-deoxyanthracyclines and methods of preparation | Pending | 16-Feb-2017 | C07H15/252 |
Monopar Therapeutics Executive Team (7)
Monopar Therapeutics Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Chandler Robinson MD | Monopar Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| Christopher Starr Ph.D | Monopar Therapeutics | Chairman & Board Member | 000 0000 |
| Michael Brown | Self | Board Member | 000 0000 |
| Raymond Anderson | Monopar Therapeutics | Board Member | 000 0000 |
Monopar Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Monopar Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Monopar Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000 000000000 | 14-Nov-2017 | 0000000000 | Drug Discovery | 00000000 |